GILEAD SCIENCES, INC. - 07 Feb 2024 Form 3 Insider Report for Kyverna Therapeutics, Inc. (KYTX)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	KYTX	Series A-2 Convertible Preferred Stock							07 Feb 2024	Common Stock	1,514,083		Direct	F1, F2
holding	KYTX	Series B Convertible Preferred Stock							07 Feb 2024	Common Stock	1,702,036		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	The convertible preferred stock is convertible at any time, at the holder's election, on a one-for-one basis, and will convert automatically upon the issuer's consummation of an initial public offering. The preferred stock has no expiration date.
F2	Reflects a 1-for-4.5511 reverse stock split of the issuer's common stock, effected on January 30, 2024.